A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
Recruiting · NCT06736275 · Registry updated 2026-05-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors | Body Weight, Body Weight Changes, Cachexia, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Thinness, Weight Loss | Recruiting | Early phase 1 | 2026-05-15 | NCT06736275 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chinese Academy of Medical Sciences | 36 |
| Jiangsu GQ Pharma Co., Ltd. | 2 |
| Jiangsu Nutai Biologics Co., Ltd | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing | China | 17 |